Clinical Efficacy Of Gamma-ray Stereotactic Body Radiotherapy Combined With Hormonal Therapy On Localized And Locally Advanced Prostate Cancer

Objective:To explore the efficacy and safety of the gamma-ray stereotactic body radiotherapy combined with hormonal therapy on localized and locally advanced prostate cancer.Methods:A restrospective analysis was carried out in localized and locally advanced prostate cancer patients from January 2005 to January 2010.A total of patients enrolled in the study were randomly divided into the control group(endocrine therapy)23 cases and the research groups(gamma-ray stereotactic body radiotherapy combined with hormonal therapy)22 cases,then they treated with intermittent maximum androgen blockade intervention.The gamma-ray stereotactic body radiation therapy was applied in the research group.After Follow-up of 5 years,the five-year incidence rate of castrate resistant prostate cancer,clinical progression-free survival,overall survival,biochemcal progression-free survival,incidence rate of castrate resistant prostate cancer in low risk?medium risk and high risk groups,off-treatment period of the first cycle,prostate-specific antigenand adverse reactions in the two groups were compared.Results:The 5-year incidence rate of castrate resistant prostate cancer in the control group and the research group were 73.9%and 22.7%respectively.The difference was statistically significant(x2=11.789,P=0.001).but the five-year clinical progression-free survival(65.2%,86.4%)and overall survival(86.9%,95.5%)were not significantly different(?2=2.722,P=0.099;x2=0.228,P=0.317).The incidence rate of castrate resistant prostate cancer in the low risk control group and the low risk research group were 0%and 0%,not showing statistically different(P=1.000).The incidence rate of castrate resistant prostate cancer in the high risk control group and the high risk research group were 100%and 62.5%,not showing statistically different(P=0.082).The incidence rate of castrate resistant prostate cancer in the medium risk control group and the medium risk research group were 70%and 0%.The difference was statistically significant(P=0.003).The biochemcal progression-free survival and off-treatment period of the first cycle in the research group were superior to that of control group(P<0.05).The main side effects in the two groups were Grade ? and ?,no grade?.The 5-year cumulative side effects in the control group were 6 cases and 14 cases in the research group,the total cumulative side effect in the two groups was significantly different(x2=6.895,P=0.009).The side effect of grade ? in the control group and the research group werel cases and 2cases,not showing statistically different(?2=0.309,P=0.579).Conclusion:The gamma-ray stereotactic body radiotherapy combined with hormonal therapy can significantly reduce the incidence rate of castrate resistant prostate cancer and extend biochemcal progression-free survival on localized and locally advanced prostate cancer.While it's side effects are light,security higher.The further research would be studied on the clinical progression-free survival and overall survival.